Improvements have recently been reported in the large PRISMA trial wherein structured SMBG showed clinical value in reducing HbA1c in non-insulin-treated T2D, suggesting that this clinical benefit may be mediated by more appropriate and timely changes in drug therapy regardless of the use of insulin [6, 7]. Here, INS is linked to type 2 diabetes mellitus.